Moleculomics to develop Covid-19 drug discovery platform

Moleculomics, based at Swansea University Medical School,
has been awarded funding from Innovate UK – the UK’s innovation agency, for
technology development to find drug treatments for Covid-19 and other viral
threats. The new in silico platform, GRASP – Generic Rapid Antiviral
Screening Platform, will seek to get ahead of emerging strains of the virus by
simulating the effects of mutations before they happen,

Moleculomics launches the Human3DProteome platform

Moleculomics has launched its flagship in silico drug discovery platform, Human3DProteome.

Human3DProteome is a comprehensive platform for whole system drug discovery, drug repurposing and toxicity screening.

Human3DProteome is a breakthrough technology for rapid discovery of better and safer drug compounds – a comprehensive in silico platform of the entire human proteome (all the receptors,

Crack It Logo

NC3Rs CRACK IT Solution: Cross-species comparative in silico platform (CRISP)

Moleculomics has gained the support of the NC3Rs through the development of a CRACK IT Solution; A technology partnering hub to accelerate the translation of technologies with 3Rs potential (‘Solutions’) by helping to identify new partners and customers to use, develop and validate the technology.  As such, a collaborative opportunity is presented to help validate their CRISP comparative in silico structural/ functional platform that identifies species differences in liver activity,
British Yeast Group 2016

The British Yeast Group Meeting 2016

The British Yeast Group Meeting 2016 was held at Swansea University and hosted by the Centre
for Cytochrome P450 Biodiversity. The conference attracted an international mix of attendees with talks ranging from fundamental eukaryotic biology to yeast as a model for human disease.

During the event, Moleculomics CEO Dr Jonathan Mullins unveiled Yeast3DProteome: A comparative structural bioinformatics platform for yeasts

Moleculomics Sponsors the British Science Festival 2016

Moleculomics Sponsors the British Science Festival 2016

Moleculomics were proud to sponsor the 2016 British Science Festival, hosted by Swansea University this year.

The British Science Festival is Europe’s longest-standing national event which connects people with scientists, engineers, technologists and social scientists. Organised by the British Science Association (BSA), the event was first held in York in 1831 and then annually at cities across the UK. 

Proteome scale structural bioinformatics platforms in drug discovery

Proteome scale structural bioinformatics platforms in drug discovery

Moleculomics founder and CEO Dr Jonathan Mullins was proud to be invited as keynote speaker at the International conference on Clinical Sciences and Drug Discovery (CSDD-2016) in Dundee earlier this year.

Highly aligned to the evolution of Moleculomics, the focus of CSDD-2016 lies in the translation of academic research findings into industry-driven drug development.

computer mouse

Moleculomics is recruiting: Bioinformatician Research Assistant

JOB: Bioinformatician Research Assistant

LOCATION: Laval, Quebec ⧉

JOB TERM: 1 years fixed term with opportunity for continuation

Moleculomics is seeking to employ a bioinformatician for the delivery of a strategically important project for the development of our fast growing company.

In this role you will be responsible for the technical delivery of a project spanning both high throughput protein structural modelling and predicted interaction of resulting protein structures with large libraries of small molecules. 

An image of some test tubes in the laboratory

Moleculomics Identify Novel Host-Pathogen Interaction Drug Targets

Moleculomics, a company who specialise in high-throughput prediction of molecular interactions using cutting-edge in silico modelling and screening tools, has recently completed a project funded by the Defence Science and Technology Laboratory’s (Dstl) Centre for Defence Enterprise (CDE). It focuses on the identification of host-pathogen interactions which can be manipulated in order to devise novel therapies to meet the UK’s current and future defence and security needs.